ArticleAmerican journal of translational research2025
Curculigoside alleviates ferroptosis in renal interstitial fibrosis by regulating the Nrf2/HO-1 signaling pathway.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRenal interstitial fibrosis (RIF) represents the final pathway in most progressive renal diseases. Curculigoside (CCG), derived from Curculigo Pilosa, affects oxidative stress and inflammation. However, the effects of CCG on RIF remain unclear. This study explored the nephroprotective role of CCG in regulating oxidative stress through the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway.
methodsBioinformatic analysis was employed to identify the targets of CCG, elucidate the underlying pathways, and analyze molecular docking results. C57BL/6 mouse models of unilateral ureteral obstruction (UUO) were established to validate the results. Morphologic changes were assessed by pathologic examination, and the expression of proteins associated with renal ferroptosis and fibrosis was analyzed by western blotting. Additionally, the levels of glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (SOD), and iron were measured.
resultsIn total, 3,532 differentially expressed genes (DEGs) were identified, comprising 2,290 upregulated and 1,242 downregulated genes. We retrieved 484 ferroptosis-related genes from the ferroptosis regulators (FerrDb) database, identifying 143 DEGs after intersecting with those from the Gene Expression Omnibus Series 217654 dataset (GSE217654). The key identified genes included nicotinamide adenine dinucleotide oxidase 4 (NOX4), activating transcription factor 3 (ATF3), mitogen-activated protein kinase 14 (MAPK14), tissue inhibitor metalloproteinase 1 (TIMP1), and early growth response 1 (EGR1). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses indicated that these genes were enriched in oxidative signaling pathways. The results exhibited the docking activity of CCG with related targets. CCG significantly alleviated histopathologic damage, reduced MDA and iron levels, and increased GSH and SOD levels. Protein analysis indicated that CCG alleviated fibrosis and enhanced the protein expression of antioxidants in UUO kidney tissues. CCG activated the Nrf2/HO-1 pathway and reduced UUO-induced ferroptosis.
conclusionsCCG may improve renal fibrosis and mitigate ferroptosis by activating the Nrf2/HO-1 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.